Annual Report 2019

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2019 155 The United Laboratories International Holdings Limited Annual Report 2019 Name of subsidiary Place of incorporation/ establishment Issued and fully paid share capital/ registered capital Attributable equity interest held by the Company Principal activities and place of operation (Note a) 2019 2018 Lynbond International Limited Hong Kong HK$10,000 100% 100% Inactive 聯邦制藥（成都）有限公司 (Note g) The PRC RMB400,000,000 0% 100% Investment holding in the PRC 珠海聯邦康知樂實業有限公司 (Note c) The PRC RMB250,000,000 100% 100% Investment holding in the PRC 珠海聯邦制藥股份有限公司 (Notes d and f) The PRC RMB1,678,396,000 100% 100% Manufacturing and sale of pharmaceutical products in the PRC 珠海樂邦制藥有限公司 (Note b) The PRC RMB12,825,000 100% 100% Investment holdings in the PRC 珠海市萬邦藥業有限公司 (Note c) The PRC RMB1,000,000 100% 100% Trading of pharmaceutical products in the PRC 珠海聯邦制藥銷售有限公司 (Note c) The PRC RMB1,000,000 100% 100% Trading of pharmaceutical products in the PRC 廣東開平金億膠囊有限公司 (Note b) The PRC RMB31,250,000 100% 100% Manufacturing and sale of soft capsules casings in the PRC 中山金億食品有限公司 (Note b) The PRC RMB8,014,500 100% 100% Investment holding in the PRC 珠海市金德福企業策劃有限公司 (Note c) The PRC RMB15,000,000 100% 100% Investment holding in the PRC 聯邦制藥（內蒙古）有限公司 (Note b) The PRC RMB2,744,000,000 100% 100% Manufacturing and sale of pharmaceutical intermediate products in the PRC 內蒙古光大聯豐生物科技有限公司 (Note c) The PRC RMB6,000,000 100% 100% Production and sale of organic fertiliser in the PRC 46. LIST OF SUBSIDIARIES (Continued)